stockportfolio.pro
Stocks / NKTR vs PGNY
NKTR vs PGNY
Nektar Therapeutics and Progyny, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Nektar Therapeutics (NKTR) | Progyny, Inc. (PGNY) | |
|---|---|---|
| Market cap | $2.0B | $2.0B |
| Revenue (latest FY) | $55.23M | $1.29B |
| Net income (latest FY) | $-164.08M | $58.52M |
| Revenue growth (5y CAGR) | -18.4% | 30.2% |
| Net margin | -297.1% | 4.5% |
| Return on equity | -182.6% | 11.3% |
| P/E ratio | — | 33.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 7 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NKTR — free Open PGNY — freeFrequently asked questions
Which is bigger, NKTR or PGNY?
Progyny, Inc. is larger by market capitalization — $2.0B versus $2.0B.
Which grows faster, NKTR or PGNY?
Over the last five fiscal years, Progyny, Inc. grew revenue faster — 30.2%/yr versus -18.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.